2Karen AM, William Thompson.A practical guide to prescribing hormone replacement therapy [J] . Drugs,1998, 56(1): 49.
3Paech K,Webb P,Kuiper GGJM,et al.Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites[J] .Science, 1997, 277:1 508.
4Brzozowski AM, Pike ACW, Dauter Z, et al.Molecular basis of agonism and antagonism in the oestrogen re ceptor [ J ] . Nat ure, 1997, 389: 753.
5Yang NN,Venugopalan MV,Hardikar S,et al. Identification of an estrogen response element activated by metabolites of 17 β estradiol and raloxifene[J] .Scien ce, 1996,273:1 222.
6Misiti S, Schomburg L, Yen PM, et al.Expression and hormonal regulation of coactivator and corepressor genes [J]. Endocrinology, 1998, 139: 2 493.
7Fisher B, Costantino JP, Wickerham DL, et al.Tamoxifen for prevention of breast cancer:NASBP P-1 Study[J].J Natl Cancer Inst,1998,90(18):1 371.
8Fisher B, Diagnam J, Bryant J, et al.Five versus more than five years of tamoxifen therapy for breast cancer patients with negtive lymph nodes and estrogen receptor-positive tumors[J] .J Natl Cancer Inst, 1996, 88:1529.
9Love RR, Mazess rb, Barden HS, et al .Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer[J] .N Eng J Med, 1992,326:852.
10Saarto T,Blomqvist C,Ehnholm C,et al.Antiatherogenic effects of adjuvant antiestrogens:a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer[J] .J Clin Oncol, 1996, 14:429.
7Sararto T, Blomqvist C, Ehnholm C et al . Antiatherogeme effects of adjuvant antiestrogens; a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with no-de-positive breast cancer. J Clin Oncol, 1996,14:429.
8Butmell Charles A, Hendriksen Barry A, Larsen Samuel D. Framleithsla og kristalform af 2 - methyl - thteno - bensodiasepin. US Patent, IS4446,1997.01.
9Gradishar W, Glusman J, Lu Yet al . Effects of highdose raloxifene in selected patients with advancedbreast carcinoma. Cancer, 2000, 88 (9) :2 047.
10Ke H Z, Qi H, Crawford DT et al . Lasofoxifene (CP2336156), a selective estrogen receptor modulator, pre2vents bone loss induced by aging and orchidectomy inthe adult rat. Endocrinology, 2000, 141 (4) : 1 338.
